Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) EBIT: 2020-2025

Historic EBIT for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to -$6.3 million.

  • Biofrontera's EBIT fell 26.57% to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 9.02%. This contributed to the annual value of -$17.2 million for FY2024, which is 24.11% up from last year.
  • According to the latest figures from Q3 2025, Biofrontera's EBIT is -$6.3 million, which was down 23.61% from -$5.1 million recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's EBIT peaked at -$1.7 million during Q4 2024, and registered a low of -$16.1 million during Q3 2021.
  • Its 3-year average for EBIT is -$5.1 million, with a median of -$5.1 million in 2024.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 587.07% in 2021, then soared by 77.40% in 2022.
  • Biofrontera's EBIT (Quarterly) stood at -$1.9 million in 2021, then plummeted by 196.86% to -$5.6 million in 2022, then soared by 30.75% to -$3.9 million in 2023, then soared by 55.71% to -$1.7 million in 2024, then decreased by 26.57% to -$6.3 million in 2025.
  • Its last three reported values are -$6.3 million in Q3 2025, -$5.1 million for Q2 2025, and -$4.5 million during Q1 2025.